SOX5 promotes breast cancer proliferation and invasion by transactivation of EZH2

Sun,Chuntao; Ban,Yunqing; Wang,Kai; Sun,Yanming; Zhao,Zhihua

doi:10.3892/ol.2019.9914

SOX5 promotes breast cancer proliferation and invasion by transactivation of EZH2

Authors:
- Chuntao Sun
- Yunqing Ban
- Kai Wang
- Yanming Sun
- Zhihua Zhao
View Affiliations

Affiliations: Department of Interventional Radiology, Weifang City People's Hospital, Weifang, Shandong 261041, P.R. China, Imaging Center, The 5th Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China, Department of Breast Surgery, Weifang City People's Hospital, Weifang, Shandong 261041, P.R. China, Department of Nuclear Medicine, Weifang City People's Hospital, Weifang, Shandong 261041, P.R. China
Published online on: January 9, 2019 https://doi.org/10.3892/ol.2019.9914
Pages: 2754-2762
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sex determining region Y‑box protein 5 (SOX5) is a transcriptional factor and serves important roles in various cancer types; however, the pathological role of SOX5 in patients with breast cancer remains unclear. In the present study, the expression and potential role of SOX5 in patients with breast cancer and in breast cancer cells was investigated. The data indicated that SOX5 was highly expressed in breast cancer tissues compared with adjacent healthy tissues, and overexpression of SOX5 was associated with a reduced overall survival rate in patients with breast cancer. Gain and loss of function studies with MTT, colony formation, wound healing and Matrigel invasion assays demonstrated that SOX5 significantly promoted breast cancer cell proliferation and invasion. The chromatin immunoprecipitation (ChIP) assay sequence, quantitative ChIP and luciferase reporter assays were used to identify enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) as a downstream target gene of SOX5. Furthermore, it was determined that ectopic expression of SOX5 increased EZH2 expression at the mRNA and protein level, while the knockdown of SOX5 decreased EZH2 expression. Additionally, the biological effect of SOX5 was investigated, and it was determined to be dependent on the regulation of EZH2 expression. The present results may provide important insights into the biological significance of SOX5 serving as a candidate therapeutic target in breast cancer progression.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Bombonati A and Sgroi DC: The molecular pathology of breast cancer progression. J Pathol. 223:307–317. 2011. View Article : Google Scholar : PubMed/NCBI
3	Hong W and Dong E: The past, present and future of breast cancer research in China. Cancer Lett. 351:1–5. 2014. View Article : Google Scholar : PubMed/NCBI
4	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
5	Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, Cristofanilli M, Dontu G, Bidaut L, Valero V, et al: Breast cancer metastasis: Challenges and opportunities. Cancer Res. 69:4951–4953. 2009. View Article : Google Scholar : PubMed/NCBI
6	Steeg PS: Targeting metastasis. Nat Rev Cancer. 16:201–218. 2016. View Article : Google Scholar : PubMed/NCBI
7	Martinez-Morales PL, Quiroga AC, Barbas JA and Morales AV: SOX5 controls cell cycle progression in neural progenitors by interfering with the WNT-beta-catenin pathway. EMBO Rep. 11:466–472. 2010. View Article : Google Scholar : PubMed/NCBI
8	Rescan PY and Ralliere C: A Sox5 gene is expressed in the myogenic lineage during trout embryonic development. Int J Dev Biol. 54:913–918. 2010. View Article : Google Scholar : PubMed/NCBI
9	Ma S, Chan YP, Woolcock B, Hu L, Wong KY, Ling MT, Bainbridge T, Webber D, Chan TH, Guan XY, et al: DNA fingerprinting tags novel altered chromosomal regions and identifies the involvement of SOX5 in the progression of prostate cancer. Int J Cancer. 124:2323–2332. 2009. View Article : Google Scholar : PubMed/NCBI
10	Chen Y, Liu W, Chao T, Zhang Y, Yan X, Gong Y, Qiang B, Yuan J, Sun M and Peng X: MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett. 272:197–205. 2008. View Article : Google Scholar : PubMed/NCBI
11	Wang D, Han S, Wang X, Peng R and Li X: SOX5 promotes epithelial-mesenchymal transition and cell invasion via regulation of twist1 in hepatocellular carcinoma. Med Oncol. 32:4612015.PubMed/NCBI
12	Zhang D and Liu S: SOX5 promotes epithelial-mesenchymal transition in osteosarcoma via regulation of Snail. J BUON. 22:258–264. 2017.PubMed/NCBI
13	Huang DY, Lin YT, Jan PS, Hwang YC, Liang ST, Peng Y, Huang CY, Wu HC and Lin CT: Transcription factor SOX-5 enhances nasopharyngeal carcinoma progression by down-regulating SPARC gene expression. J Pathol. 214:445–455. 2008. View Article : Google Scholar : PubMed/NCBI
14	Pei XH, Lv XQ and Li HX: Sox5 induces epithelial to mesenchymal transition by transactivation of Twist1. Biochem Biophys Res Commun. 446:322–327. 2014. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Gonzalez ME, Moore HM, Li X, Toy KA, Huang W, Sabel MS, Kidwell KM and Kleer CG: EZH2 expands breast stem cells through activation of NOTCH1 signaling. Proc Natl Acad Sci USA. 111:3098–3103. 2014. View Article : Google Scholar : PubMed/NCBI
17	Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, et al: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA. 100:11606–11611. 2003. View Article : Google Scholar : PubMed/NCBI
18	Truax AD, Thakkar M and Greer SF: Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells. PLoS One. 7:e360132012. View Article : Google Scholar : PubMed/NCBI
19	Wuebben EL and Rizzino A: The dark side of SOX2: Cancer-a comprehensive overview. Oncotarget. 8:44917–44943. 2017. View Article : Google Scholar : PubMed/NCBI
20	Bulstrode H, Johnstone E, Marques-Torrejon MA, Ferguson KM, Bressan RB, Blin C, Grant V, Gogolok S, Gangoso E, Gagrica S, et al: Elevated FOXG1 and SOX2 in glioblastoma enforces neural stem cell identity through transcriptional control of cell cycle and epigenetic regulators. Genes Dev. 31:757–773. 2017. View Article : Google Scholar : PubMed/NCBI
21	Liu K, Xie F, Gao A, Zhang R, Zhang L, Xiao Z, Hu Q, Huang W, Huang Q, Lin B, et al: SOX2 regulates multiple malignant processes of breast cancer development through the SOX2-miR-181a-5p, miR-30e-5p-TUSC3 axis. Mol Cancer. 16:622017. View Article : Google Scholar : PubMed/NCBI
22	Inoue H, Takahashi H, Hashimura M, Eshima K, Akiya M, Matsumoto T and Saegusa M: Cooperation of Sox4 with β-catenin-p300 complex in transcriptional regulation of the slug gene during divergent sarcomatous differentiation in uterine carcinosarcoma. BMC Cancer. 16:532016. View Article : Google Scholar : PubMed/NCBI
23	Bilir B, Osunkoya AO, Wiles WG VI, Sannigrahi S, Lefebvre V, Metzger D, Spyropoulos DD, Martin WD and Moreno CS: SOX4 is essential for prostate tumorigenesis initiated by PTEN ablation. Cancer Res. 76:1112–1121. 2016. View Article : Google Scholar : PubMed/NCBI
24	Sun R, Jiang B, Qi H, Zhang X, Yang J, Duan J, Li Y and Li G: SOX4 contributes to the progression of cervical cancer and the resistance to the chemotherapeutic drug through ABCG2. Cell Death Dis. 6:e19902015. View Article : Google Scholar : PubMed/NCBI
25	Yoon TM, Kim SA, Cho WS, Lee DH, Lee JK, Park YL, Lee KH, Lee JH, Kweon SS, Chung IJ, et al: SOX4 expression is associated with treatment failure and chemoradioresistance in oral squamous cell carcinoma. BMC Cancer. 15:8882015. View Article : Google Scholar : PubMed/NCBI
26	Tiwari N, Tiwari VK, Waldmeier L, Balwierz PJ, Arnold P, Pachkov M, Meyer-Schaller N, Schübeler D, van Nimwegen E and Christofori G: Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell. 23:768–783. 2013. View Article : Google Scholar : PubMed/NCBI
27	Hasegawa S, Nagano H, Konno M, Eguchi H, Tomokuni A, Tomimaru Y, Asaoka T, Wada H, Hama N, Kawamoto K, et al: A crucial epithelial to mesenchymal transition regulator, Sox4-Ezh2 axis is closely related to the clinical outcome in pancreatic cancer patients. Int J Oncol. 48:145–152. 2016. View Article : Google Scholar : PubMed/NCBI